Session Information
Date: Sunday, November 13, 2016
Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment with ADA resulted in significant sustained improvements in RA-related work productivity and activity impairment (AI) in Japanese patients with RA (DOI: 10.1136/annrheumdis-2016-eular.3068). The objective of this study is to assess economic impact of ADA on Japanese RA patients in the real-world setting.
Methods: In this 48-week, multicenter, prospective single-cohort study (ANOUVEAU study), 1,973 RA patients treated with ADA were asked to complete self-reported questionnaire on their work every 12 weeks. Of those, the data of 1,196 patients were available and were included in this analysis. The cohort was stratified into the following baseline employment status: Paid Worker (PW), employed for ≥ 35 hours/week n=649, Part Time Worker (PTW), employed for < 35 hours/week n=172 and Home maker (HM), non-employed n=375. Work-related outcomes including absenteeism (work time missed), presenteeism (impairment while working) and Overall Work Impairment (OWI) as well as AI were evaluated using the Work Productivity and Activity Impairment questionnaire for Rheumatoid Arthritis (WPAI-RA). The amount of productivity loss was estimated by multiplying absenteeism, presenteeism and OWI by the national average occupational wage rates for PW and PTW, and by multiplying AI by the estimated wage rate for domestic work for HM. Primary outcomes were 12-week change in productivity loss and cumulative reductions achieved with ADA treatment during the study period.
Results: The amounts of productivity loss estimated from OWI at baseline and 12-week productivity loss at week 12, week 24, week 36, and week 48 were 5,106 USD, 3,322 USD (p< 0.01), 2,978 USD (p< 0.01), 2,901 USD (p< 0.01), and 2,828 USD (p< 0.01) for PW, and 3,791 USD, 2,899 USD (p= 0.11), 2,618 USD (p= 0.02), 2,424 USD (p< 0.01), and 2,278 USD (p< 0.01) for PTW, respectively (1 USD= 110 JPY, p-value for change from baseline, t-test). Moreover, the productivity loss estimated from AI at week 12, 24, 36 and 48 were 4,261 USD, 2,954 USD (p< 0.01), 2,618 USD (p< 0.01), 2,623 USD (p< 0.01) and 2,558 USD for HM, respectively (p< 0.01). The cumulative reductions in productivity loss for OWI, obtained from ADA treatment, at week 48 were 6,740 USD for PW and 3,148 USD for PTW. The reduction for AI at week 48 was 6,239 USD for HM.
Conclusion: In this study, the annual amounts of reduction in productivity loss of RA patients achieved from ADA treatment were estimated 6,740 USD for PW, 3,148 USD for PTW and 6,239 USD for HW. Given that the average annual income in Japan in 2014 was 37,727 USD, the results show that ADA has considerable economic impact on RA patients.
To cite this abstract in AMA style:
Tanaka Y, Yamazaki K, Nakajima R, Komatsu S, Agata N, Igarashi A, Tango T, Takeuchi T. Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/economic-impact-of-adalimumab-treatment-in-japanese-patients-with-rheumatoid-arthritis-from-the-anouveau-study-clinicaltrial-gov-nct01346488/. Accessed .« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/economic-impact-of-adalimumab-treatment-in-japanese-patients-with-rheumatoid-arthritis-from-the-anouveau-study-clinicaltrial-gov-nct01346488/